Følg
Professor Michael S. Hofman
Professor Michael S. Hofman
Consultant Physician, Peter MacCallum Cancer Centre & University of Melbourne
Verificeret mail på petermac.org
Titel
Citeret af
Citeret af
År
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised …
MS Hofman, N Lawrentschuk, RJ Francis, C Tang, I Vela, P Thomas, ...
The Lancet 395 (10231), 1208-1216, 2020
13032020
Sensitivity, specificity, and predictors of positive 68Ga–prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and …
M Perera, N Papa, D Christidis, D Wetherell, MS Hofman, DG Murphy, ...
European urology 70 (6), 926-937, 2016
10652016
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
MS Hofman, J Violet, RJ Hicks, J Ferdinandus, SP Thang, T Akhurst, ...
The Lancet Oncology 19 (6), 825-833, 2018
9392018
Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and distribution …
M Perera, N Papa, M Roberts, M Williams, C Udovicich, I Vela, ...
European urology 77 (4), 403-417, 2020
7542020
[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ...
The Lancet 397 (10276), 797-804, 2021
6262021
Somatostatin Receptor Imaging with 68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation
MS Hofman, WFE Lau, RJ Hicks
Radiographics 35 (2), 500-516, 2015
4862015
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging …
J Calais, F Ceci, M Eiber, TA Hope, MS Hofman, C Rischpler, ...
The Lancet Oncology 20 (9), 1286-1294, 2019
3702019
Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019
S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, A Briganti, ...
European urology 77 (4), 508-547, 2020
3542020
International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers
A Biggi, A Gallamini, S Chauvie, M Hutchings, L Kostakoglu, M Gregianin, ...
Journal of Nuclear Medicine 54 (5), 683-690, 2013
3352013
Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes
J Violet, P Jackson, J Ferdinandus, S Sandhu, T Akhurst, A Iravani, ...
Journal of Nuclear Medicine 60 (4), 517-523, 2019
3292019
Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls
MS Hofman, RJ Hicks, T Maurer, M Eiber
Radiographics 38 (1), 200-217, 2018
3122018
Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial
S Siva, M Bressel, DG Murphy, M Shaw, S Chander, J Violet, KH Tai, ...
European urology 74 (4), 455-462, 2018
2892018
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale
A Gallamini, SF Barrington, A Biggi, S Chauvie, L Kostakoglu, ...
Haematologica 99 (6), 1107, 2014
2882014
High management impact of Ga‐68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours
MS Hofman, G Kong, OC Neels, P Eu, E Hong, RJ Hicks
Journal of medical imaging and radiation oncology 56 (1), 40-47, 2012
2672012
Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration …
J Violet, S Sandhu, A Iravani, J Ferdinandus, SP Thang, G Kong, ...
Journal of Nuclear Medicine 61 (6), 857-865, 2020
2382020
E-PSMA: the EANM standardized reporting guidelines v1. 0 for PSMA-PET
F Ceci, DE Oprea-Lager, L Emmett, JA Adam, J Bomanji, J Czernin, ...
European journal of nuclear medicine and molecular imaging 48, 1626-1638, 2021
2272021
The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the …
L Emmett, J Buteau, N Papa, D Moon, J Thompson, MJ Roberts, K Rasiah, ...
European urology 80 (6), 682-689, 2021
2222021
Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer
WP Fendler, M Weber, A Iravani, MS Hofman, J Calais, J Czernin, H Ilhan, ...
Clinical Cancer Research 25 (24), 7448-7454, 2019
2212019
Prostate-specific membrane antigen ligands for imaging and therapy
M Eiber, WP Fendler, SP Rowe, J Calais, MS Hofman, T Maurer, ...
Journal of Nuclear Medicine 58 (Supplement 2), 67S-76S, 2017
2132017
Is there still a role for SPECT–CT in oncology in the PET–CT era?
RJ Hicks, MS Hofman
Nature reviews Clinical oncology 9 (12), 712-720, 2012
1782012
Systemet kan ikke foretage handlingen nu. Prøv igen senere.
Artikler 1–20